Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chen, Vincent Lingzhi | - |
dc.contributor.author | Yeh, Ming Lun | - |
dc.contributor.author | Le, An Kim | - |
dc.contributor.author | Jun, Myung Joon | - |
dc.contributor.author | Saeed, Waqar Khalid | - |
dc.contributor.author | Yang, Ju Dong | - |
dc.contributor.author | Huang, Chung Feng | - |
dc.contributor.author | Lee, HY | - |
dc.contributor.author | Tsai, Pei Chien | - |
dc.contributor.author | Lee, Mei Hsuan | - |
dc.contributor.author | Giama, N. | - |
dc.contributor.author | Kim, N. G. | - |
dc.contributor.author | Nguyen, P. P. | - |
dc.contributor.author | Dang, H. | - |
dc.contributor.author | Ali, H. A. | - |
dc.contributor.author | Zhang, N. | - |
dc.contributor.author | Huang, J. -F. | - |
dc.contributor.author | Dai, C. -Y. | - |
dc.contributor.author | Chuang, W. -L. | - |
dc.contributor.author | Roberts, L. R. | - |
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Lim, Y. -S. | - |
dc.contributor.author | Yu, M. -L. | - |
dc.contributor.author | Nguyen, M. H. | - |
dc.date.accessioned | 2021-08-02T13:27:29Z | - |
dc.date.available | 2021-08-02T13:27:29Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2018-07 | - |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/16835 | - |
dc.description.abstract | Background: Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) worldwide. It remains incompletely understood in the real world how anti-viral therapy affects survival after HCC diagnosis. Methods: This was an international multicentre cohort study of 2518 HBV-related HCC cases diagnosed between 2000 and 2015. Cox proportional hazards models were utilised to estimate hazard ratios (HR) with 95% (CI) for anti-viral therapy and cirrhosis on patients' risk of death. Results: Approximately, 48% of patients received anti-viral therapy at any time, but only 17% were on therapy at HCC diagnosis (38% at US centres, 11% at Asian centres). Anti-viral therapy would have been indicated for >60% of the patients not on anti-viral therapy based on American criteria. Patients with cirrhosis had lower 5-year survival (34% vs 46%; P<0.001) while patients receiving anti-viral therapy had increased 5-year survival compared to untreated patients (42% vs 25% with cirrhosis and 58% vs 36% without cirrhosis; P<0.001 for both). Similar findings were seen for other patient subgroups by cancer stages and cancer treatment types. Anti-viral therapy was associated with a decrease in risk of death, whether started before or after HCC diagnosis (adjusted HR 0.62 and 0.79, respectively; P<0.001). Conclusions: Anti-viral therapy improved overall survival in patients with HBV-related HCC across cancer stages and treatment types but was underutilised at both US and Asia centres. Expanded use of anti-viral therapy in HBV-related HCC and better linkage-to-care for HBV patients are needed. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jun, Dae Won | - |
dc.identifier.doi | 10.1111/apt.14801 | - |
dc.identifier.scopusid | 2-s2.0-85048326841 | - |
dc.identifier.wosid | 000434634800005 | - |
dc.identifier.bibliographicCitation | ALIMENTARY PHARMACOLOGY & THERAPEUTICS, v.48, no.1, pp.44 - 54 | - |
dc.relation.isPartOf | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.citation.title | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.citation.volume | 48 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 44 | - |
dc.citation.endPage | 54 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | NUCLEOS(T)IDE ANALOG | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | TERM | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | PACIFIC | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/apt.14801 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.